Clinical Trials
- Liver
Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)
- Ages18 years - 75 years
- GenderBoth
- Liver
Saroglitazar Primary Biliary Cholangitis
- Immune System
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)
- Ages18 years - 75 years
- GenderBoth
- Liver, Digestive System
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) (ELATIVE)
- Ages18 years - 75 years
- GenderBoth